ALX ONCOLOGY LIMITED

ALX Oncology Limited is a clinical‑stage biopharmaceutical company dedicated to expanding treatment options for cancer patients. By harnessing the power of the immune system, the firm develops novel therapies that aim to raise the standard of care now and into the future. Their flagship candidate, evorpacept, is being positioned as a potential cornerstone of next‑generation immuno‑oncology, with a scientifically‑validated, synergistic approach that integrates cutting‑edge research and clinical expertise.

The company’s focus lies in creating immune‑boosting agents that can be combined with existing treatments to deliver a more powerful, coordinated attack on tumours. Through rigorous development plans and a tenacious, science‑driven team, ALX Oncology seeks to translate its innovative platform into tangible benefits for patients and healthcare providers alike. Their commitment to collaboration and breakthrough science underpins a clear mission: to advance the future of cancer therapies and improve outcomes for those living with the disease.